242 related articles for article (PubMed ID: 22392783)
1. [The aspects of pricing policy in Azerbaijan pharmaceutical sector].
Dzhalilova KI; Alieva KIa
Georgian Med News; 2012 Jan; (202):48-53. PubMed ID: 22392783
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
Stargardt T; Schreyögg J; Busse R
Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
[TBL] [Abstract][Full Text] [Related]
3. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
4. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
5. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
6. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
7. Competition and the Reference Pricing Scheme for pharmaceuticals.
Ghislandi S
J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
Vogel RJ
Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
[TBL] [Abstract][Full Text] [Related]
9. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
10. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
11. Examining the link between price regulation and pharmaceutical R&D investment.
Vernon JA
Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
[TBL] [Abstract][Full Text] [Related]
12. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
Augurzky B; Göhlmann S; Gress S; Wasem J
Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
[TBL] [Abstract][Full Text] [Related]
13. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
Mueller MT; Frenzel A
Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
[TBL] [Abstract][Full Text] [Related]
14. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
Felder S
Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
[TBL] [Abstract][Full Text] [Related]
15. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
16. [Impact Reimbursement Act on the pharmaceutical market in Poland].
Giermaziak W
Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
Wu J; Xu J; Liu G; Wu J
Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
Lichtenberg FR
Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
[TBL] [Abstract][Full Text] [Related]
19. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
20. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
Ioannides-Demos LL; Ibrahim JE; McNeil JJ
Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]